Tuberous sclerosis complex is a genetic disorder caused by mutations in either the TSC1 or TSC2 gene that can result in the growth of hamartomas in multiple organ systems. Subependymal giant cell astrocytomas are slow-growing brain tumors associated primarily with tuberous sclerosis complex. They are usually located in the ventricles, often near the foramen of Monro, where they can cause an obstruction if they grow too large, leading to increased intracranial pressure. Surgery to remove a tumor has been the mainstay of treatment but can be associated with postoperative morbidity and mortality. Not all tumors and/or patients are suitable for surgery. The recent development of mammalian target of rapamycin inhibitors that target the pathway affected by TSC1/TSC2 mutations offers a novel pharmacotherapeutic option for these patients. We review the timing and use of surgery versus pharmacotherapy for the treatment of subependymal giant cell astrocytoma in patients with tuberous sclerosis complex.
OsborneJPFryerAWebbD. Epidemiology of tuberous sclerosis. Ann N Y Acad Sci. 1991;615:125–127.
3.
SancakONellistMGoedbloedM. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype: phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex. Eur J Hum Genet. 2005;13:731–741.
4.
OrlovaKACrinoPB. The tuberous sclerosis complex. Ann N Y Acad Sci. 2010;1184:87–105.
5.
van SlegtenhorstMde HoogtRHermansC. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277:805–808.
6.
European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75:1305–1315.
7.
HuangJManningBD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J. 2008;412:179–190.
8.
WullschlegerSLoewithRHallMN.TOR signaling in growth and metabolism. Cell. 200610;124:471–484.
9.
HayNSonenbergN. Upstream and downstream of mTOR. Genes Dev. 2004;18:1926–1945.
10.
ZhangYGaoXSaucedoLJ. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol. 2003;5:578–581.
CucciaVZuccaroGSosaF. Subependymal giant cell astrocytoma in children with tuberous sclerosis. Childs Nerv Syst. 2003;19:232–243.
14.
AdriaensenMESchaefer-ProkopCMStijnenT. Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature. Eur J Neurol. 2009;16:691–696.
15.
BuccolieroAMFranchiACastiglioneF. Subependymal giant cell astrocytoma (SEGA): is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study. Neuropathology. 2009;29:25–30.
16.
LouisDNOhgakiHWiestlerOD. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropsychiatrica. 2007;114:97–109.
GrajkowskaWKotulskaKJurkiewiczE. Subependymal giant cell astrocytomas with atypical histological features mimicking malignant gliomas. Folia Neuropathol. 2011;49:39–46.
20.
HymanMHWhittemoreVH. National Institutes of Health consensus conference: tuberous sclerosis complex. Arch Neurol. 2000;57:662–665.
21.
BerhoumaM. Management of subependymal giant cell tumors in tuberous sclerosis complex: the neurosurgeon's perspective. World J Pediatr. 2010;6:103–110.
22.
TorresOARoachESDelgadoMR. Early diagnosis of subependymal giant cell astrocytoma in patients with tuberous sclerosis. J Child Neurol. 1998;13:173–177.
23.
MoaveroRPinciMBombardieriRCuratoloP. The management of subependymal giant cell tumors in tuberous sclerosis: a clinician's perspective. Childs Nerv Syst. 2011;27:1203–1210.
24.
RoszkowskiMDrabikKBarszczSJozwiakS. Surgical treatment of intraventricular tumors associated with tuberous sclerosis. Childs Nerv Syst. 1995;11:335–339.
25.
MatsumuraHTakimotoHShimadaN. Glioblastoma following radiotherapy in a patient with tuberous sclerosis. Neurol Med Chir (Tokyo). 1998;38:287–291.
26.
de RibaupierreSDorfmullerGBulteauC. Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate?Neurosurgery. 2007;60:83–89.
EkiciMAKumandasSPerH. Surgical timing of the subependymal giant cell astrocytoma (SEGA) with the patients of tuberous sclerosis complex. Turk Neurosurg. 2011;21:315–324.
29.
AminSCarterMEdwardsRJ. The outcome of surgical management of subependymal giant cell astrocytoma in tuberous sclerosis complex. Eur J Paediatr Neurol. 2013;17:36–44.
30.
BeemsTGrotenhuisJA. Subependymal giant-cell astrocytoma in tuberous sclerosis: endoscopic images and the implications for therapy. Minim Invasive Neurosurg. 2001;44:58–60.
31.
CaiRDiX. Combined intra- and extra-endoscopic techniques for aggressive resection of subependymal giant cell astrocytomas. World Neurosurg. 2010;73:713–718.
32.
RodgersSDBassaniLWeinerHLHarterDH. Stereotactic endoscopic resection and surgical management of a subependymal giant cell astrocytoma: case report. J Neurosurg Pediatr. 2012;9:417–420.
33.
CappabiancaPCinalliGGangemiM. Application of neuroendoscopy to intraventricular lesions. Neurosurgery. 2008;62(suppl 2):575–597.
34.
BeaumontTLLimbrickDDSmythMD. Advances in the management of subependymal giant cell astrocytoma. Childs Nerv Syst. 2012;28:963–968.
35.
WangLWShiauCYChungWY. Gamma Knife surgery for low-grade astrocytomas: evaluation of long-term outcome based on a 10-year experience. J Neurosurg. 2006;105(suppl):127–132.
36.
ParkKJKanoHKondziolkaDNiranjanA. Gamma Knife surgery for subependymal giant cell astrocytomas. Clinical article. J Neurosurg. 2011;114:808–813.
KidaYKobayashiTMoriY. Gamma Knife radiosurgery for low-grade astrocytomas: results of long-term follow up. J Neurosurg. 2000;93(suppl 3):42–46.
39.
SunPKohrmanMLiuJ. Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis. Curr Med Res Opin. 2012;28:657–663.
40.
SunPKruegerDLiuJ. Surgical resection of subependymal giant cell astrocytomas (SEGAs) and changes in SEGA-related conditions: a US national claims database study. Curr Med Res Opin. 2012;28:651–656.
41.
KumarRSinghV. Subependymal giant cell astrocytoma: a report of five cases. Neurosurg Rev. 2004;27:274–280.
42.
JiangTJiaGMaZLuoSZhangY. The diagnosis and treatment of subependymal giant cell astrocytoma combined with tuberous sclerosis. Childs Nerv Syst. 2011;27:55–62.
Afinitor (everolimus tablets for oral administration). Afinitor Disperz (everolimus tablets for oral suspension) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.
45.
KruegerDACareMMHollandK. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363:1801–1811.
46.
FranzDNBelousovaESparaganaS. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381:125–132.
47.
KruegerDACareMMAgricolaK. Everolimus long-term safety and efficacy in subependymal giant-cell astrocytoma. Neurology. 2013;80:574–580.
48.
FranzDN. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis. Exp Rev Anticancer Ther. 2011;11:1181–1192.
49.
KotulskaKChmielewskiDBorkowskaJ. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Eur J Paediatr Neurol. 2013April 6. doi.org/10.1016/j.ejpn.2013.03.002. [Epub ahead of print]
50.
PortaCOstantoSRavaudA. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer. 2011;47:1287–1298.
51.
FranzDNLeonardJTudorC. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006;59:490–498.
52.
KoenigMKButlerIJNorthrupH. Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol. 2008;23:1238–1239.
53.
BircaAMercierCMajorP. Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex. J Neurosurg Pediatr. 2010;6:381–384.
54.
LamCBouffetETaboriU. Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors. Pediatr Blood Cancer. 2010;54:476–479.
55.
FranzDNAgricolaKDTudorCAKruegerDA. Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. J Child Neurol. 2013;28:602–607.
56.
YalonMBen-SiraLConstantiniSTorenA. Regression of subependymal giant cell astrocytomas with RAD001 (everolimus) in tuberous sclerosis complex. Childs Nerv Syst. 2011;27:179–181.
57.
Perek-PolnikMJozwiakSJurkiewiczE. Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex. Eur J Paediatr Neurol. 2012;16:83–85.
58.
BisslerJJKingswoodJCRadzikowskaE. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381:817–824.
59.
WieneckeRFacklerILinsenmaierU. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis. 2006;48:e27–e29.
60.
BisslerJJMcCormackFXYoungLR. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358:140–151.
61.
HofbauerGFMarcollo-PiniACorsencaA. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol. 2008;159:473–475.
62.
TurnerSGPetersKBVredenburghJJ. Everolimus tablets for patients with subependymal giant cell astrocytoma. Exp Opin Pharmacother. 2011;12:2265–2269.
63.
KruegerDCareMAgricolaK. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology. 2013;80:574–580.
